Health care of Kyrgyzstan
Zdravoohraneniye Kyrgyzstana

ISSN 1694-8068 (Print)

ISSN 1694-805X (Online)

Situation on drug resistance of TB causiator in 2019-2020 in the Kyrgyz Republic

Situation on drug resistance of TB causiator in 2019-2020 in the Kyrgyz Republic
Полный текст Full text Толук текст  

Abstract

The article describes the situation of drug resistance of the causative agent of tuberculosis, provides data on the effectiveness of anti-tuberculosis therapy in patients with pulmonary tuberculosis with multidrug resistance, as well as indicators of the success of treatment of RU/MDR TB in short-term and individual regimens. The indicators of treatment coverage of patients with RU/M/XDR TB, the proportion of pulmonary and extrapulmonary forms, age-sex structure, categories of previously treated and new cases were studied. Data on a cohort of cases confirmed by various tests for drug sensitivity are presented. An important place is given to the study of the growth rates of cases with TB and HIV coinfection in 2019- 2020. The important role of patients' access to antiretroviral therapy due to the limitations associated with the COVID-19 pandemic was noted. According to the results of the study, an unreliable increase in the proportion of XDR TB cases was established, the highest level of XDR TB in Jalal-Abad, Osh regions, the State Penitentiary Service and the city of Osh, among which the share of XDR TB in the Osh region increased by more than 2 times. The analysis of the results showed the need to increase the coverage of short-term treatment regimens due to the high success rates of treatment of RU/MDR TB than other regimens. However, in the Kyrgyz Republic, the percentage of coverage of shortterm innovation regimes in the country does not exceed 12%. High success rates of treatment of RU/MDR TB with shortterm and individual regimens, including Bdq/Dlm, have been established. The effectiveness of XDR TB treatment in IR therapy with new drugs is higher than without their inclusion.

About the authors

Токтогонова Атыркуль Акматбековна, д.м.н., заместитель директора по науке, Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика

Жаныбеков Илияс Жаныбекович, ведущий специалист, преподаватель, врач- анестезиолог-реаниматолог, Международная школа медицины, кафедра патологии, Бишкек, Кыргызская Республика

Toktogonova Atyrkul Akmatbekovna, MD,Deputy director for science, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Zhanybekov Ilias Zhanybekovich, leading specialist, teacher, anesthesiologist-resuscitator, International School of Medicine, Department of Pathology,Bishkek, Kyrgyz Republic

Токтогонова Атыркул Акматбековна, медицина илимдеринин доктору, илим иштери боюнча директордун орун басары Кыргыз Республикасынын Саламаттыкты сактоо министрлигинин Улуттук фтизиатрия борбору, Бишкек, Кыргыз Республикасы

Жаныбеков Илиас Жаныбекович, башкы адис, окутуучу, анестезиолог-реаниматолог, эл аралык медицина мектеби, бөлүмү Патология, Бишкек, Кыргыз Республикасы

References

1. Report on the global fight against tuberculosis. VAZ, 2019. - 2 p.
2. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
3. Drug resistance of M. tuberculosis (historical aspects, modern level of knowledge)//Burmistrova I.A., Samoilova A.G., Tyulkova
T.E. et al. / Tuberculosis and lung diseases. 2020;98(1):54-61.
4. Tuberculosis with multiple and broad drug resistance of Mycobacterium tuberculosis in the Russian Federation // Ergeshov A.E., Punga V.V., Rusakova L. I., Sterlikov S.A., etc. / Avicenna's Bulletin, vol. 20, No. 2-3, 2018, pp. 314-319.
5. Tiberi S., Zumla A., Migliori G.B. Multidrug and Extensively Drug resistant Tuberculosis: Epidemiology, Clinical Features, Management and Treatment. Infect Dis Clin North Am. 2019;33(4):1063‐1085. doi:10.1016/j.idc.2019.09.002.
6. Токтогонова, А.А. Лекарственная устойчивость возбудителя туберкулеза к препаратам первого ряда в Кыргызской Республике [Текст] А.А. Токтогонова // Здравоохранение Кыргызстана. – 2012. – №1. – С.42-45.Toktogonova, A.A. Drug resistance of the causative agent of tuberculosis to first-line drugs in the Kyrgyz Republic [Text] A.A. Toktogonova // Healthcare of Kyrgyzstan. - 2012. – No. 1. – p.42-45.

1. Report on the global fight against tuberculosis. VAZ, 2019. - 2 p.
2. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
3. Drug resistance of M. tuberculosis (historical aspects, modern level of knowledge)//Burmistrova I.A., Samoilova A.G., Tyulkova T.E. et al. / Tuberculosis and lung diseases. 2020;98(1):54-61.
4. Tuberculosis with multiple and broad drug resistance of Mycobacterium tuberculosis in the Russian Federation // Ergeshov A.E., Punga V.V., Rusakova L. I., Sterlikov S.A., etc. / Avicenna's Bulletin, vol. 20, No. 2-3, 2018, pp. 314-319.
5. Tiberi S., Zumla A., Migliori G.B. Multidrug and Extensively Drug resistant Tuberculosis: Epidemiology, Clinical Features, Management and Treatment. Infect Dis Clin North Am. 2019;33(4):1063‐1085. doi:10.1016/j.idc.2019.09.002.
6. Toktogonova, A.A. Drug resistance of the causative agent of tuberculosis to first-line drugs in the Kyrgyz Republic [Text] A.A. Toktogonova // Healthcare of Kyrgyzstan. - 2012. – No. 1. – p.42-45.

1. Report on the global fight against tuberculosis. VAZ, 2019. - 2 p.
2. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
3. Drug resistance of M. tuberculosis (historical aspects, modern level of knowledge)//Burmistrova I.A., Samoilova A.G., Tyulkova
T.E. et al. / Tuberculosis and lung diseases. 2020;98(1):54-61.
4. Tuberculosis with multiple and broad drug resistance of Mycobacterium tuberculosis in the Russian Federation // Ergeshov A.E., Punga V.V., Rusakova L. I., Sterlikov S.A., etc. / Avicenna's Bulletin, vol. 20, No. 2-3, 2018, pp. 314-319.
5. Tiberi S., Zumla A., Migliori G.B. Multidrug and Extensively Drug resistant Tuberculosis: Epidemiology, Clinical Features, Management and Treatment. Infect Dis Clin North Am. 2019;33(4):1063‐1085. doi:10.1016/j.idc.2019.09.002.
6. Токтогонова, А.А. Лекарственная устойчивость возбудителя туберкулеза к препаратам первого ряда в Кыргызской Республике [Текст] А.А. Токтогонова // Здравоохранение Кыргызстана. – 2012. – №1. – С.42-45.Toktogonova, A.A. Drug resistance of the causative agent of tuberculosis to first-line drugs in the Kyrgyz Republic [Text] A.A. Toktogonova // Healthcare of Kyrgyzstan. - 2012. – No. 1. – p.42-45.

Для цитирования

Токтогонова А.А., Жаныбеков И.Ж. Ситуация по лекарственной устойчивости возбудителя туберкулеза в 2019-2020 гг. в Кыргызской Республике.Здравоохранение Кыргызстана 2022, № 2, с. 33-40. https://dx.doi.org/10.51350/zdravkg202262333

For citation

Toktogonova A.A., Zhanybekov I.Zh. Situation on drug resistance of TB causiator in 2019-2020 in the Kyrgyz republic Health care of Kyrgyzstan 2022,No. 2, pp. 33-40. https://dx.doi.org/10.51350/zdravkg202262333

 

 

 

Цитата үчүн

Токтогонова А.А., Жаныбеков И.Ж. Кыргыз Республикасында кѳп дарыларга туруктуу кургак учук боюнча 2019-2020-жылдардагы абал. Кыргызстандын саламаттык сактоо илимий-практикалык журналы 2022, no 2, б. 33-40.  https://dx.doi.org/10.51350/zdravkg202262333

 

Authors Toktogonova A.A., Zhanybekov I. Zh.
Link doi.org https://doi.org/10.51350/zdravkg202262333
Pages 33-40
Keywords drug resistance of the pathogen, extensive drug resistance, efficacy, tuberculosis, Kyrgyz Republic, prevalence, treatment regimen, tuberculosis situation
Russian
Об авторах

Токтогонова Атыркуль Акматбековна, д.м.н., заместитель директора по науке, Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика

Жаныбеков Илияс Жаныбекович, ведущий специалист, преподаватель, врач- анестезиолог-реаниматолог, Международная школа медицины, кафедра патологии, Бишкек, Кыргызская Республика

Полный текст

PDF (RUS)

Список литературы

1. Report on the global fight against tuberculosis. VAZ, 2019. - 2 p.
2. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
3. Drug resistance of M. tuberculosis (historical aspects, modern level of knowledge)//Burmistrova I.A., Samoilova A.G., Tyulkova
T.E. et al. / Tuberculosis and lung diseases. 2020;98(1):54-61.
4. Tuberculosis with multiple and broad drug resistance of Mycobacterium tuberculosis in the Russian Federation // Ergeshov A.E., Punga V.V., Rusakova L. I., Sterlikov S.A., etc. / Avicenna's Bulletin, vol. 20, No. 2-3, 2018, pp. 314-319.
5. Tiberi S., Zumla A., Migliori G.B. Multidrug and Extensively Drug resistant Tuberculosis: Epidemiology, Clinical Features, Management and Treatment. Infect Dis Clin North Am. 2019;33(4):1063‐1085. doi:10.1016/j.idc.2019.09.002.
6. Токтогонова, А.А. Лекарственная устойчивость возбудителя туберкулеза к препаратам первого ряда в Кыргызской Республике [Текст] А.А. Токтогонова // Здравоохранение Кыргызстана. – 2012. – №1. – С.42-45.Toktogonova, A.A. Drug resistance of the causative agent of tuberculosis to first-line drugs in the Kyrgyz Republic [Text] A.A. Toktogonova // Healthcare of Kyrgyzstan. - 2012. – No. 1. – p.42-45.

Для цитирования

Токтогонова А.А., Жаныбеков И.Ж. Ситуация по лекарственной устойчивости возбудителя туберкулеза в 2019-2020 гг. в Кыргызской Республике.Здравоохранение Кыргызстана 2022, № 2, с. 33-40. https://dx.doi.org/10.51350/zdravkg202262333

English
About authors

Toktogonova Atyrkul Akmatbekovna, MD,Deputy director for science, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Zhanybekov Ilias Zhanybekovich, leading specialist, teacher, anesthesiologist-resuscitator, International School of Medicine, Department of Pathology,Bishkek, Kyrgyz Republic

Full text

PDF (RUS)

References

1. Report on the global fight against tuberculosis. VAZ, 2019. - 2 p.
2. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
3. Drug resistance of M. tuberculosis (historical aspects, modern level of knowledge)//Burmistrova I.A., Samoilova A.G., Tyulkova T.E. et al. / Tuberculosis and lung diseases. 2020;98(1):54-61.
4. Tuberculosis with multiple and broad drug resistance of Mycobacterium tuberculosis in the Russian Federation // Ergeshov A.E., Punga V.V., Rusakova L. I., Sterlikov S.A., etc. / Avicenna's Bulletin, vol. 20, No. 2-3, 2018, pp. 314-319.
5. Tiberi S., Zumla A., Migliori G.B. Multidrug and Extensively Drug resistant Tuberculosis: Epidemiology, Clinical Features, Management and Treatment. Infect Dis Clin North Am. 2019;33(4):1063‐1085. doi:10.1016/j.idc.2019.09.002.
6. Toktogonova, A.A. Drug resistance of the causative agent of tuberculosis to first-line drugs in the Kyrgyz Republic [Text] A.A. Toktogonova // Healthcare of Kyrgyzstan. - 2012. – No. 1. – p.42-45.

For citation

Toktogonova A.A., Zhanybekov I.Zh. Situation on drug resistance of TB causiator in 2019-2020 in the Kyrgyz republic Health care of Kyrgyzstan 2022,No. 2, pp. 33-40. https://dx.doi.org/10.51350/zdravkg202262333

 

 

 

Kyrgyz
Авторлор жөнүндө

Токтогонова Атыркул Акматбековна, медицина илимдеринин доктору, илим иштери боюнча директордун орун басары Кыргыз Республикасынын Саламаттыкты сактоо министрлигинин Улуттук фтизиатрия борбору, Бишкек, Кыргыз Республикасы

Жаныбеков Илиас Жаныбекович, башкы адис, окутуучу, анестезиолог-реаниматолог, эл аралык медицина мектеби, бөлүмү Патология, Бишкек, Кыргыз Республикасы

Толук текст

PDF (RUS)

Шилтемелер

1. Report on the global fight against tuberculosis. VAZ, 2019. - 2 p.
2. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
3. Drug resistance of M. tuberculosis (historical aspects, modern level of knowledge)//Burmistrova I.A., Samoilova A.G., Tyulkova
T.E. et al. / Tuberculosis and lung diseases. 2020;98(1):54-61.
4. Tuberculosis with multiple and broad drug resistance of Mycobacterium tuberculosis in the Russian Federation // Ergeshov A.E., Punga V.V., Rusakova L. I., Sterlikov S.A., etc. / Avicenna's Bulletin, vol. 20, No. 2-3, 2018, pp. 314-319.
5. Tiberi S., Zumla A., Migliori G.B. Multidrug and Extensively Drug resistant Tuberculosis: Epidemiology, Clinical Features, Management and Treatment. Infect Dis Clin North Am. 2019;33(4):1063‐1085. doi:10.1016/j.idc.2019.09.002.
6. Токтогонова, А.А. Лекарственная устойчивость возбудителя туберкулеза к препаратам первого ряда в Кыргызской Республике [Текст] А.А. Токтогонова // Здравоохранение Кыргызстана. – 2012. – №1. – С.42-45.Toktogonova, A.A. Drug resistance of the causative agent of tuberculosis to first-line drugs in the Kyrgyz Republic [Text] A.A. Toktogonova // Healthcare of Kyrgyzstan. - 2012. – No. 1. – p.42-45.

Цитата үчүн

Токтогонова А.А., Жаныбеков И.Ж. Кыргыз Республикасында кѳп дарыларга туруктуу кургак учук боюнча 2019-2020-жылдардагы абал. Кыргызстандын саламаттык сактоо илимий-практикалык журналы 2022, no 2, б. 33-40.  https://dx.doi.org/10.51350/zdravkg202262333

 

Views: 3282
Copyright MAXXmarketing GmbH
JoomShopping Download & Support